BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Significant Increase in Short Interest

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the recipient of a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 202,300 shares, a growth of 113.4% from the January 31st total of 94,800 shares. Currently, 5.9% of the company’s stock are sold short. Based on an average trading volume of 373,300 shares, the days-to-cover ratio is presently 0.5 days.

BriaCell Therapeutics Stock Performance

NASDAQ:BCTX opened at $3.67 on Friday. BriaCell Therapeutics has a 52 week low of $3.33 and a 52 week high of $52.93. The firm has a 50-day moving average price of $5.77 and a two-hundred day moving average price of $9.61. The firm has a market cap of $13.61 million, a price-to-earnings ratio of -0.28 and a beta of 1.59.

BriaCell Therapeutics (NASDAQ:BCTX) last issued its quarterly earnings results on Monday, December 16th. The company reported ($3.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($2.10). As a group, sell-side analysts forecast that BriaCell Therapeutics will post -2.45 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright upped their target price on shares of BriaCell Therapeutics from $15.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd.

Institutional Investors Weigh In On BriaCell Therapeutics

Several large investors have recently made changes to their positions in the business. Vontobel Holding Ltd. grew its position in BriaCell Therapeutics by 37.5% during the fourth quarter. Vontobel Holding Ltd. now owns 110,000 shares of the company’s stock valued at $62,000 after buying an additional 30,000 shares during the period. Cantor Fitzgerald L. P. purchased a new position in BriaCell Therapeutics in the fourth quarter valued at about $32,000. Finally, Virtu Financial LLC bought a new position in shares of BriaCell Therapeutics during the 4th quarter valued at approximately $27,000. 15.42% of the stock is owned by hedge funds and other institutional investors.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.